Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160744 · ClinicalTrials.gov registry record · Phase 2
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT01160744 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 280 participants.
The verdict
NCT01160744, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
- BIOLOGICAL IMC-1121B (ramucirumab)
- DRUG Carboplatin (AUC 6)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2010-09 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160744
The ClinicalTrials.gov registry entry for NCT01160744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01160744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160744 about?
NCT01160744 is a clinical study titled "A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + car...
What is the current status of trial NCT01160744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2010-09. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01160744?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), IMC-1121B (ramucirumab) (BIOLOGICAL), Carboplatin (AUC 6) (DRUG).
Who is sponsoring clinical trial NCT01160744?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.